Treatment of the animal model with mesenchymal stem cell-derived exosomes significantly restored colonic FXR alongside improved gut microbiota metagenomics and metabolomics, resulting in relieving macroscopic and microscopic features of IBD (Ocansey et al., 2022; Xu et al., 2022). This evidence concerns the gene NR1H4 and inflammatory bowel disease.